Welcome to our dedicated page for P3 HEALTH PARTNERS news (Ticker: PIII), a resource for investors and traders seeking the latest updates and insights on P3 HEALTH PARTNERS stock.
P3 Health Partners Inc. reports developments in population health management, value-based primary care and physician-led care coordination. The company supports community providers through administrative services, clinical operations, data-driven care enablement and partnerships tied to Medicare Advantage, accountable care organizations and delegated-risk arrangements.
Recurring updates include quarterly results, guidance, revenue trends, capitated revenue per member, medical margin, adjusted EBITDA and operating changes in the Care Enablement Model. Company news also covers payer and provider agreements, ACO management services, market expansion, investor conference participation and joint venture activity such as the P3 Commonwealth Innovation MSO.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
P3 Health Partners Inc. (NASDAQ: PIII) reported its Q4 and full-year 2022 financial results, with a notable 40% increase in capitated revenue to $254.0 million. However, the company faced a substantial net loss of $532.3 million, primarily due to a goodwill impairment charge of $463.5 million. For the full year, P3's at-risk Medicare Advantage membership grew by 50% to 100,400, with total revenues reaching $1.0 billion, a 66% increase from the previous year. Looking forward, P3 anticipates achieving Adjusted EBITDA positivity by early 2024 and has provided fiscal 2023 guidance with total revenues projected between $1.2 billion and $1.25 billion.
P3 Health Partners Inc. (NASDAQ: PIII) announced a definitive agreement for a private placement of securities, expected to yield approximately $90 million in gross proceeds. The lead investors are affiliates of Chicago Pacific Founders and Leavitt Partners. The company will issue 79.9 million units at about $1.12 per unit, which includes one share of common stock and 0.75 of a warrant for each unit. The funds will be used for general corporate purposes, and the transaction's closing is anticipated for April 6, 2023.
P3 Health Partners Inc. (NASDAQ: PIII) announced it will release its fourth-quarter 2022 and full-year 2022 results on March 31, 2023, before the market opens. Management will host a conference call and webcast at 8:30 AM ET on the same day to discuss corporate and financial updates. P3 is a physician-led population health management company with over 2,800 affiliated primary care providers across five states. The call details will be provided on the company’s investor page, and an archived recording will be available for 90 days post-event.
P3 Health Partners Inc. (NASDAQ: PIII) plans to release its financial results for the fourth quarter and full year ending December 31, 2022, on March 30, 2023. The company will also file its Annual Report on Form 10-K on the same day. An investor call and webcast are scheduled for 4:30 PM ET to discuss the financial performance and provide a corporate update. P3 Health Partners focuses on improving healthcare through a network of over 2,800 affiliated primary care providers across five states. Further details will be available on their investor relations page.
P3 Health Partners Inc. (NASDAQ: PIII) announced its intention to file the Annual Report on Form 10-K by March 30, 2023. The delay is attributed to an administrative issue related to the delayed audit for 2021. P3 reaffirmed its 2022 revenue guidance of $1.025 billion to $1.075 billion, representing a 61% to 69% increase year-over-year. They expect at-risk Medicare Advantage membership to exceed 100,000, a 35% rise from 2021. The 2023 guidance includes revenue expectations of $1.20 billion to $1.25 billion and an Adjusted EBITDA loss of $40 million to $60 million. P3 anticipates achieving Adjusted EBITDA profitability by 2024.